Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome

Stopped early · Phase 2

Conditions studied: Myelodysplastic Syndrome (MDS)

In brief

Study TLK199.2107 is a multicenter, single arm, open-label Phase 2 study of oral ezatiostat (Telintra®) in patients with lenalidomide (Revlimid®) refractory or resistant, red blood cell (RBC) transfusion-dependent, Low to Intermediate-1 IPSS risk, del5q Myelodysplastic Syndrome (MDS).

Key facts

Study ID
NCT01422486
Run by
Telik
People needed
2
Starts
2011-10-01
Expected to finish
2013-02-01
Last updated by the study team
2013-11-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.